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Abstract
Background: Intranasal inoculation of Streptococcus pneumoniae D39 serotype 2 causes fatal
pneumonia in mice. The cytotoxic and inflammatory properties of pneumolysin (PLY) have been
implicated in the pathogenesis of pneumococcal pneumonia.
Methods: To examine the role of PLY in this experimental model we performed ELISA assays for
PLY quantification. The distribution patterns of PLY and apoptosis were established by
immunohistochemical detection of PLY, caspase-9 activity and TUNEL assay on tissue sections
from mice lungs at various times, and the results were quantified with image analysis. Inflammatory
and apoptotic cells were also quantified on lung tissue sections from antibody treated mice.
Results: In bronchoalveolar lavages (BAL), total PLY was found at sublytic concentrations which
were located in alveolar macrophages and leukocytes. The bronchoalveolar epithelium was PLY-
positive, while the vascular endothelium was not PLY reactive. The pattern and extension of cellular
apoptosis was similar. Anti-PLY antibody treatment decreased the lung damage and the number of
apoptotic and inflammatory cells in lung tissues.
Conclusion: The data strongly suggest that in vivo lung injury could be due to the pro-apoptotic
and pro-inflammatory activity of PLY, rather than its cytotoxic activity. PLY at sublytic
concentrations induces lethal inflammation in lung tissues and is involved in host cell apoptosis,
whose effects are important to pathogen survival.
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Background
Streptococcus pneumoniae is the major pathogen of commu-
nity-acquired pneumonia and one of the most common
causes of death due to infectious disease in industrialized
countries. Pneumococcus usually colonizes the nasophar-
ynx of humans asymptomatically, although on occasions
it passes from this niche to the lungs, brain, and blood
[1,2]. This can lead to diseases associated with high mor-
bidity and mortality such as pneumonia, septicemia, and
meningitis. Pneumolysin (PLY) is a 53-kDa toxic protein
that belongs to the family of antigenically related thiol-
activated, cholesterol-binding cytolysins [3]. At high lev-
els, PLY is lytic to all cells with cholesterol-containing
membranes [4]. In contrast to other characterized
cytolysins, it is located in the cytoplasm and released dur-
ing bacterial growth and lysis [5]. PLY contributes to dis-
ease mortality, and mutants of the ply gene have reduced
virulence in mice after pulmonary challenge [6-8]. PLY
has proven to be a protective immunogen in mice [9,10]
against challenge with a range of capsular serotypes [11].
As such, PLY is considered to be an excellent candidate to
include in a pneumococcal vaccine [1,12].
Pneumococci are capable of inducing apoptosis in respi-
ratory tree epithelium [13,14], endothelium, and neuro-
nal cells [15,16]. S. pneumoniae produces two
morphologically distinct forms of programmed cell death
[15]. The apoptotic activity of PLY in dendritic and cere-
bral endothelial cells is caspase-independent [15,17,18].
Caspase-dependent and TLR-4-mediated apoptosis is elic-
ited by S. pneumoniae serotype 3 in nasopharyngeal epi-
thelium in a murine model of nasal colonization [14].
Microbe-induced apoptosis may represent a major mech-
anism by which pathogenic bacteria avoid detection and
destruction by the innate immune system [19]. Certain
pathogens use virulence factors to dismantle host defenses
through inhibition of anti-apoptotic signaling pathways
[20,21]. PLY induces apoptosis [18,22], activates comple-
ment [23], and releases proinflammatory mediators
[24,25]. In this study, we examined the role of PLY in
mediating lung damage in experimental acute bacterial
pneumonia induced by S. pneumoniae D39 serotype 2.
Methods
Murine infection
Mice were intranasally inoculated as previously described
[26]. Briefly, outbred MF-1 mice (Oxon, Harland Olac
Ltd., Bicester, England) weighing 30 ± 3 g were lightly
anaesthetized with 3% (v/v) halothane over oxygen (3–4
l/min) using a methacrylate box connected to Fluovac 240
(Anaesthetizing system, Cheshire, England) and intrana-
sally infected with a lethal dose of 5 × 106 CFU of S. pneu-
moniae D39 serotype 2 NCTC 7466 (Spanish Type Culture
Collection, Valencia, Spain) in 50 μl of phosphate-buff-
ered saline (PBS), applied atraumatically to the tip of the
nose and involuntarily inhaled. Animal studies were per-
formed in accordance with the guidelines of the Institu-
tional Animal Care and Use Committee of the University
of Oviedo (Spain).
Bronchoalveolar lavages (BAL)
Groups of 3 mice were deeply anaesthetized 12, 24, 36,
48, 60 and 72 h after infection. The trachea was surgically
exposed and cannulated. BAL was performed by a single
injection of 0.5 ml of PBS into the trachea, followed by
aspiration through a 25-G needle. Quantitative cultures
from BAL were then performed on blood agar to deter-
mine the number of colony-forming units (CFU).
PLY detection by ELISA
Quantification of PLY was performed by ultrasensitive
enzyme-linked immunoassay (ELISA) as described previ-
ously [27]. Briefly, Triton X-100 to 0.05% was added to
the BAL samples and incubated 30 min at 37°C to allow
pneumococcal lysis. Flat-bottomed polystyrene Combi-
plate White Breakable (Labsystems, Helsinki, Finland)
plates were coated with 1 μg/well of PLY-7 (IgG1 kappa,
anti-PLY mouse monoclonal antibody) in carbonate-
bicarbonate buffer 0.05 M pH 9.6 for 6 h at 37°C. Plates
were washed at each step with PBS plus 0.1% Tween-20,
blocked with blocking buffer prepared according to the
instructions of the manufacturer of ELISA-Light™ Chemi-
luminescent Detection System (Tropix, Applied Biosys-
tems, Bedford, MA, USA). The samples were then added to
wells and incubated at 37°C for 1 h with shaking. Once
washed six times, plates were incubated with rabbit IgG
polyclonal anti-PLY diluted in blocking buffer and incu-
bated 30 min at 37°C. An alkaline phosphatase conju-
gated goat anti-rabbit IgG secondary antibody (Sigma
Chemicals Co.) was used at a 1:5000 dilution and incu-
bated as above. Plates were loaded on a Luminoskan RS
(Labsystems) luminometer and the wells were automati-
cally filled with substrate/enhancer solution (0.4 mM
CSPDR with 1× Sapphire-II™) and incubated for 10 min.
The lower detection limit of ELISA assay was 30 pg/ml of
PLY.
Antibody treatment
Mice intranasally infected with S. pneumoniae D39 sero-
type 2 were treated with anti-PLY rabbit IgG as previously
described [26]. Briefly, mice were injected in the tail vein
with 100 μg of anti-PLY IgG [26] in 200 μl of sterile non-
pyrogenic PBS 1 h before and 36 h after intranasal infec-
tion with S. pneumoniae. Control mice were injected with
100 μg of non-immune rabbit IgG (Sigma) or 200 μl of
sterile non-pyrogenic PBS. Groups of mice were deeply
anaesthetized 12, 24, 36, 48, 60 and 72 h after infection,
and lungs were removed, fixed in 10% buffered formalin,
and embedded in paraffin.Respiratory Research 2007, 8:3 http://respiratory-research.com/content/8/1/3
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Histopathology and immunohistochemistry
For confocal examinations, 5 μm sections were washed in
fresh xylene for 5 min, rehydrated through a series of
graded alcohols and air dried at room temperature. 50 μl
of SYTO 9 green fluorescent nucleic acid stain (LIVE/
DEAD Bac-Light Bacterial Viability Kit, Molecular Probes,
L-13152) were added to tissue sections, and the cover-
slide was placed on top after staining for at least 10 min-
utes in the dark. The samples were then examined by Z
stacking under a Leica TCS-SP2-AOBS confocal laser scan-
ning microscope at a wavelength of 488 nm excitation
and 530 nm (green) emission. Images were captured
using the Leica Confocal Software. For histology examina-
tions, sections were stained with hematoxylin and eosin
(H&E) and viewed by light microscopy. For immunos-
taining, sections mounted on slides were baked for 30
min at 60°C and then washed twice in fresh xylene for 5
min each to remove paraffin. The slides were rehydrated
through a series of graded alcohols, and washed in dis-
tilled water for 3 min. Endogenous peroxidase activity was
blocked using a peroxidase-blocking solution (DAKO,
Glostrup, Denmark) and non-specific binding was
blocked with 1% bovine serum albumin (BSA) in Tris-
buffered saline (TBS) (100 mM Tris, pH 8.0; 150 mM
NaCl). After antigen retrieval, lung tissue sections were
incubated with rabbit polyclonal anti-PLY IgG [26,27]
diluted to 1:1000 in 1% BSA-TBS for 16 h at 4°C and vis-
ualized using the DAKO EnVision™ +Kit (DAKO). For cas-
pase-9 detection, lung tissue sections were incubated with
rabbit anti-caspase-9 mouse specific antibody (Cell Sign-
aling Technology Inc., Beverly, MA, USA) diluted to 1:100
in 1% BSA-TBS for 16 h at 4°C, followed by washing in
TBS-0.1% Tween-20, and visualized as above. The TUNEL
assays of tissue sections were conducted using the In Situ
Cell Death Detection Kit, POD (Roche Applied Science,
Penzberg, Germany) following manufacturer's instruc-
tions. Sections were washed and counterstained briefly
with hematoxylin. Four sections separated by at least 200
μm were studied per animal and examined using a light
microscope Leica DMR (Leica Microsystems Wetzlar
GmbH, Germany) coupled to a high resolution colour
Leica MPS30 camera. Analysis was carried out with the
UTHSCSA Image Tool for Windows Version 3.0 software
programme (University of Texas Health Science Center,
San Antonio, TX, USA). Tissue areas were selected using
systematic random sampling and cells were counted in
five areas delineated by a grid. For co-localization of PLY,
TUNEL, and caspase-9, three adjacent sections were co-
stained. Thereafter, we acquired images and identified
matching cells in the sections by overlaying the PLY
immunostaining. A total of five sections were analyzed for
each time point.
Statistical analysis
Statistical differences in total PLY amounts at different
time points were analyzed by the nonparametric Mann-
Whitney U test. Correlation between PLY and CFU was
performed by nonparametric Spearman r-test. Statistical
differences in the percentage of positive cells of PLY-,
TUNEL- and caspase-9-staining, percentage of caspase-9
positive cells, and numbers of infiltrating cells among
treatment groups were calculated by two-way ANOVA fol-
lowed by the Bonferroni test. All statistical analyses were
performed using Prism (v.4.00 for Windows; GraphPad
Software, San Diego, CA). The limit of statistical signifi-
cance was a P value of 0.05.
Results
PLY quantification and pneumococci localization
Quantification of PLY was performed in bronchoalveolar
lavages (BAL) obtained at different time points during
pneumococcal pneumonia from mice infected intrana-
sally with S. pneumoniae D39 serotype 2 (Figure 1A). PLY
was undetectable in BAL samples after removal of bacteria
by centrifugation. In contrast, PLY was detected after lysis
of bacteria, showing the highest level at 12 h post-infec-
tion (approximately 1000 pg/ml) compared with other
time points (P < 0.05). A positive correlation was found
between concentrations of total PLY and number of bac-
teria present in BAL (r2 = 0.5204, P = 0.0224) (Figure 1B).
To investigate whether changes in PLY amounts during
pneumonia were associated with different localizations of
bacteria in the lungs, an examination of tissue samples
was performed by confocal microscopy.
Pneumococcal DNA was stained and bacteria were recog-
nized as diplococcal forms, which were not present in
uninfected lung tissues (Figure 1C). Analysis of the z-
stacks obtained on the confocal microscope revealed that
both intra-and intercellular pneumococci were found in
infiltration areas, and after 24 h post-infection pneumo-
cocci were observed inside capillary vessels (Figure 1D).
Bacteria were not observed inside endothelial or epithelial
cells.
PLY and apoptosis localization
PLY localization was performed by specific immunostain-
ing in lung tissues from mice during progression of exper-
imental pneumococcal pneumonia. At 12 h post-
infection, PLY staining was detected in resident alveolar
macrophages (Figure 2A). After 24 h post-infection, leu-
kocytes located in perivascular and peribronchial infiltra-
tion areas and bronchial epithelium showed PLY-stain.
Vascular endothelium was PLY-stained at no time during
pneumococcal infection. No staining was observed in
lungs from non-infected mice.Respiratory Research 2007, 8:3 http://respiratory-research.com/content/8/1/3
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Concentrations of PLY and bacteria localization in lungs of mice infected with S. pneumoniae D39 serotype 2 Figure 1
Concentrations of PLY and bacteria localization in lungs of mice infected with S. pneumoniae D39 serotype 2. 
(A) Amounts of total PLY were quantified in BAL after lysis of bacteria. Each symbol represents one mouse, and horizontal 
bars represent medians. Results are representative of three independent experiments. Groups were compared by nonpara-
metric Mann-Whitney U test. * P < 0.05. (B) Correlation between CFU and PLY in BAL. Dots represent the means of CFU ver-
sus PLY concentration from three mice at the same time points of Fig. 1A Correlation was performed by nonparametric 
Spearman r-test. (C) Confocal images of lung tissue sections from uninfected mice. (D) Representative lung tissue sections 
from pneumococci infected mice showing intra-vessel, intra-cytoplasmic and intercellular bacteria localization. Blood vessel (v), 
alveolar space (a), bronchiole (b). Scale bars 8 μm. All images were captured after a Z-stack analysis of the samples.Respiratory Research 2007, 8:3 http://respiratory-research.com/content/8/1/3
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Apoptosis in lung tissues of mice infected with S. pneumoniae D39 serotype 2 Figure 2
Apoptosis in lung tissues of mice infected with S. pneumoniae D39 serotype 2. (A) Distribution patterns of PLY and 
apoptosis in representative lung sections from mice intranasally infected with S. pneumoniae D39 serotype 2. PLY was estab-
lished by staining with anti-PLY rabbit antibodies. Apoptosis was assessed by active caspase-9 staining and in situ TUNEL assay. 
No staining was observed in lung tissues from uninfected mice. At 12 h post-infection, resident alveolar macrophages were 
positively stained with anti-PLY, anti-caspase-9, and TUNEL (arrow heads). Infiltrating leukocytes (24 h post-infection) and 
bronchial epithelium (48 h post-infection) were stained with anti-PLY, anti-caspase-9, and TUNEL, respectively (arrow heads). 
Note non-stained vascular endothelium. Blood vessel (v), alveolar space (a), bronchiole (b). Scale bars 50 μm. (B) Apoptosis 
and PLY in lung tissues from untreated mice during pneumococcal pneumonia. Apoptosis was identified by immunohistochem-
ical detection of active caspase-9 and by in situ TUNEL assay. PLY was stained with anti-PLY rabbit antibodies. Adjacent sec-
tions were co-stained for co-localization of PLY, TUNEL, and caspase-9. Five sections were analyzed in each time point. 
Statistical differences were not found for a comparison of number of PLY, caspase-9, and TUNEL positive cells as determined 
by two-way ANOVA followed by the Bonferroni test. (C) Comparison of caspase-9 positive cells in lung tissues from anti-PLY 
IgG-, control IgG-, and PBS-treated mice. Percentage of caspase-9 stained cells was calculated with respect to total cells 
counted in random areas of lung tissue sections. Results are means ± SD of 3 mice and are representative of three independent 
experiments. *, P < 0.05 for a comparison of anti-PLY IgG-treated mice with PBS-treated mice, and +,P < 0.05 for a comparison 
of anti-PLY IgG with control IgG-treated mice, as determined by two-way ANOVA followed by the Bonferroni test.Respiratory Research 2007, 8:3 http://respiratory-research.com/content/8/1/3
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Apoptosis localization in lung tissues during pneumococ-
cal pneumonia was performed by in situ-TUNEL assay and
by specific immunostaining of active caspase-9. TUNEL-
and caspase-9-staining were located in alveolar macro-
phages at 12 h post-infection (Figure 2A). Leukocytes sit-
uated in areas of cellular infiltration, and bronchial
epithelia appeared progressively stained after 24 h post-
infection. Neither TUNEL nor caspase-9 staining was
found in vascular endothelium. Apoptosis staining was
not observed in lungs from non-infected mice.
Because the anti-PLY and anti-caspase-9 antisera available
for immunohistochemistry had been raised in rabbits, we
could not perform double staining on the same tissue sec-
tion. For co-localization of PLY, TUNEL, and caspase-9,
three adjacent sections were co-stained. Counting the
number of positive cells per unit area in consecutive sec-
tions, it was shown that there were no statistical differ-
ences in the number of cells staining for PLY, TUNEL, and
caspase-9 (P > 0.05) (Figure 2B).
To determine the pro-apoptotic activity of PLY, the
number of caspase-9 stained cells was compared in lung
tissue sections obtained at different times during pneu-
mococcal pneumonia from PBS-, control IgG-, and anti-
PLY IgG-treated mice. Lung tissue sections from anti-PLY
IgG-treated mice have a lower percentage of caspase-9
stained cells than PBS- (P < 0.01) and control IgG-treated
mice (P < 0.05), at 48 h, 60 h and 72 h post-infection (Fig-
ure 2C). Analogous results were obtained from the
number of TUNEL stained cells (data not shown).
Leukocyte recruitment
To determine PLY pro-inflammatory activity, the number
of leukocytes was compared in lung tissue of PBS-, control
IgG-, and anti-PLY IgG-treated pneumococcus-infected
mice (Figure 3). Lungs from anti-PLY IgG-treated mice
(Figure 3A) had a lower number of inflammatory cells
than control IgG-treated mice (Figure 3B). H&E-stained
lung sections from PBS-treated mice resembled those
obtained from the control IgG group. Although PBS-
treated mice revealed more infiltrating leukocytes than
mice treated with control IgG, no statistical differences
were found (Figure 3C), even though clinical differences
in survival time had previously been shown [26].
Discussion
In this study, we attempted to explore the relationship
between PLY and the lung injury observed during the pro-
gression of pneumococcal infection in a mouse intranasal
challenge model [26]. In pneumococcal pneumonia, the
cytolytic activity of PLY has been implicated in lung colo-
nization, breakdown of the capillary-epithelial barrier,
and bloodstream dissemination of the microorganisms.
The results of our experiments demonstrate that levels of
PLY in BAL are related to the bacterial burden. The signif-
icant decrease in number of bacteria after 12 h of infection
is probably due to the host response, and was also
observed in another intranasal model of pneumococcal
pneumonia [28]. PLY expression in lungs has been previ-
ously demonstrated by immunofluorescence staining
[29]. In CSF of animals with experimental pneumococcal
meningitis concentrations of PLY up to 4.34 μg/ml were
measured [30], while in human CSF, PLY was detected at
concentrations of up to 180 ng/ml [31]. To the best of our
knowledge, this is the first report of toxin quantification
during experimental pneumococcal pneumonia.
Our findings showed low amounts of PLY quantified
either before (< 30 pg/ml) or after pneumococcal lysis (<
1000 pg/ml), which have been shown to be sublytic in
various cellular types. PLY is a cholesterol-dependent
cytolysin capable of making pores in virtually all choles-
terol-containing membranes [4], although it affects dis-
tinct cellular types differently [32]. PLY causes half-
maximal lysis of endothelial and epithelial cell types at
concentrations of approximately 15 HU/ml [33,34]. It
was also reported that only very high concentrations of
PLY (1 to 20 μg/ml) have cytotoxic effects in alveolar epi-
thelial cells [13,35]. In isolated perfused rat lungs, 100
HU/ml of toxin caused extensive damage to the alveolar
epithelium [36]. Recently, it has been shown that applica-
tion of 0.25 or 2.5 μg of PLY aerosolized or infused into
isolated murine lungs, led to impressive vascular leakage
and formation of pulmonary edema, while sub-cytolytic
PLY doses (0.001–0.1 μg) caused gap formation and mod-
erate generation of stress fibers [37]. Concentrations of
0.1 μg/ml are not cytotoxic for fibroblast [12] or brain
microvascular endothelial cells [38], while in ependymal
models, 1 μg of PLY caused complete tissue destruction
[39]. In general, concentrations of PLY under 10 ng/ml are
sublytic, and concentrations necessary for a direct cyto-
toxic effect of PLY are higher than those causing immu-
nomodulatory or functional interference [31]. The
concentrations of free toxin measured in BAL are possibly
underestimates of the amounts of PLY released by bacte-
ria, since an unknown portion of the toxin liberated from
bacteria probably binds quickly to the lung tissues [31].
PLY amounts in BAL should be only taken into account
together with the histological examination of the tissues.
In this regard, there was an inverse relation between bac-
terial load/PLY concentrations and tissue damage. A
decrease in CFU, probably due to bacterial lysis, produced
an increase in lung injury, possibly due to the released
toxin.
The match between PLY- and apoptosis-positive cellular
types provides strong support for the pro-apoptotic role of
PLY. The marked decrease in apoptotic cells in anti-PLY
IgG-treated mice corroborates that PLY has an importantRespiratory Research 2007, 8:3 http://respiratory-research.com/content/8/1/3
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role in apoptosis. Although apoptosis in alveolar macro-
phages has been associated with bacterial internalization
[40], programmed cell death directly induced by PLY has
been described in alveolar macrophages and nasopharyn-
geal epithelium [14,41]. S. pneumoniae produces two mor-
phologically distinct forms of programmed cell death
[15]. We found TUNEL- and caspase-9 positive staining,
suggesting that both apoptosis pathways could be
induced by pneumococci in lung tissues. Confirmation of
this finding could be evaluated by using pneumococci ply-
negative mutants [7], although isogenic PLY-negative
mutants of D39 exhibited slower growth in the lungs, and
the maintenance of the same rate of progression of infec-
tion would be required to prove the direct effect of the
toxin. Moreover, PLY and/or other microbial factors
including cell wall components that can trigger induction
of apoptosis in the host have been identified [22], and a
relation between alveolar macrophage apoptosis and
pneumococcal inoculum has been demonstrated [42].
Hence, anti-PLY antibody treatment should only neutral-
Comparison of the level of inflammation of lung tissue among anti-PLY IgG-, control IgG-, and PBS-treated mice infected with  S. pneumoniae D39 serotype 2 Figure 3
Comparison of the level of inflammation of lung tissue among anti-PLY IgG-, control IgG-, and PBS-treated 
mice infected with S. pneumoniae D39 serotype 2. Histological appearance of representative lungs from mice infected 
intranasally with S. pneumoniae serotype 2 and treated with anti-PLY IgG (A), and control IgG (B). Numerous leukocytes can be 
seen in the peribronchial and perivascular areas, and considerable vascular distension and hemorrhage take place during the 
progression of pneumococcal colonization. Lungs of mice treated with anti-PLY IgG reveal alveoli, bronchioles, and vessels 
structurally normal, with no signs of acute inflammation and lower leukocyte infiltration. Blood vessel (v), alveolar space (a), 
bronchiole (b). Scale bars 50 μm. (C) Numbers of infiltrating cells were counted in random areas of lung tissue sections H&E-
stained. Results are means ± SD of 3 mice and are representative of three independent experiments. *, P < 0.05 for a compar-
ison of anti-PLY IgG- treated mice with PBS-treated mice, and +,P < 0.05 for a comparison of anti-PLY IgG with control IgG-
treated mice, as determined by two-way ANOVA followed by the Bonferroni test.Respiratory Research 2007, 8:3 http://respiratory-research.com/content/8/1/3
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ize the pro-apoptotic effects of the toxin and, furthermore,
we could not discount the possibility that a decrease in
bacterial load could lead to a decrease in cellular apopto-
sis.
Reports in the literature have suggested that the TUNEL
assay detects DNA fragmentation from both necrotic and
apoptotic nuclei [43]. In our study, there was no signifi-
cant difference between TUNEL- and caspase-9 positive
cell numbers, suggesting that apoptosis was the major
cause of cell death in pneumococcal-infected lung tissues
in our model. Although necrosis induced by pneumococci
has been observed in vitro [13,44], necrosis during non-
resolving pneumonia in vivo has not been found [45,46].
It has been reported that the interaction of PLY with TLR-
4-containing cells, such as macrophages, leukocytes and
epithelial cells, mediates apoptosis as a mechanism of
host defense against pneumococcal infection [14,47]. In
contrast, TLR4 was only protective against a low inoculum
in another model of pneumococcal pneumonia [45].
In our pneumococcal pneumonia model, apoptosis of
alveolar macrophages, leukocytes and bronchial epithe-
lial cells was not associated with a host benefit, since the
inoculum we use is 100% lethal in mice. Pathogen-
induced modulation of the host cell-death pathway may
eliminate key immune cells or promote evasion of host
defences that can limit infection [19]. Apoptosis of resi-
dent alveolar macrophages 12 h after infection removes
the first line of host defense in innate immunity, and
apoptosis of bronchial epithelium after 24 h post-infec-
tion eliminates the first physical barrier against pneumo-
coccal dissemination. Leukocyte apoptosis was found in
areas of cellular infiltration during pneumococcal infec-
tion. Up-regulation of leukocyte genes encoding key effec-
tors of apoptosis is another pathogen-driven mechanism
to evade host immunity after phagocytosis of bacteria
[48]. Our results strongly suggest that apoptosis removes
cells that have a key role in combating the infecting organ-
ism, and the consequential effect might be on other
aspects of the immune cell function different from reduc-
ing inflammation.
Sublytic PLY concentrations and non-staining of the vas-
cular endothelium with anti-PLY antibodies suggest that
the pore-forming capability of PLY is not the only agent
responsible for damage to vascular endothelial barriers.
Hence, the vascular distension that takes place during
infection may pave the way for pneumococci to reach the
bloodstream, despite the fact that pneumococcal transcy-
tosis through microvascular endothelial cells [49] could
also contribute to bloodstream dissemination. The rela-
tive contribution of the cytotoxic and proinflammatory
capacities of PLY to pulmonary damage has been contro-
versial. The findings from a mouse model of intratracheal
challenge using large amounts of PLY (40 ng/mouse)
indicated that lung injury resulted from a direct cytotoxic
effect of the toxin and was independent of recruited leu-
kocytes [50].
Pneumococci induce the expression of pro-inflammatory
and chemotactic cytokines by lung epithelium, thus con-
tributing to leukocyte invasion [35]. It is well documented
that PLY induces inflammatory events during pneumo-
coccal pneumonia [1], and the interaction of PLY with
host immune cells has been shown to induce the release
of inflammatory mediators [8,24,25,47]. Our findings
reveal that administration of anti-PLY antibodies pro-
duces a marked decrease in inflammation, lung injury,
and leukocyte infiltration. The interaction of PLY with
TLR4 stimulates the inflammatory response in macro-
phages independently of the cytolytic properties of the
toxin [47]. Mutants lacking the ply gene show a decreased
infiltration of leukocytes in foci of infection [28]. Exagger-
ated inflammatory responses mediated by PLY may favor
microbial survival by promoting premature, auto-oxida-
tive exhaustion of phagocytes and oxidative dysfunction
of B and T lymphocytes [24].
Conclusion
We have previously demonstrated that passive adminis-
tration of antibodies to PLY protects mice against pneu-
mococcal pneumonia [26]. Our current findings indicate
that the capacity of PLY to trigger inflammatory cell activ-
ity could play the major role in inducing the tissue dam-
age that is observed in our model of pneumococcal
pneumonia. Taken together, our results indicate that PLY
at sublytic concentrations induces lethal inflammation in
lung tissues and could be involved in apoptosis of cells of
the host immune system, which is important to pathogen
survival.
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